Mono Pharmacare reported an 89% decline in consolidated net profit to ₹35.28 lakh for the financial year ended March 31, 2026, down from ₹309.02 lakh in the previous year. Revenue from operations for the year decreased to ₹16569.19 lakh from ₹16834.49 lakh in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results for the year at a meeting held on July 16, 2026.

Financial Performance

The standalone net profit for FY26 fell to ₹35.30 lakh from ₹309.02 lakh in the previous year. Standalone revenue from operations increased to ₹9291.24 lakh from ₹8264.08 lakh in FY25. Total expenses for the year rose to ₹9248.83 lakh compared to ₹8140.33 lakh in the prior year. Earnings per share (EPS) for the year stood at ₹0.20, down from ₹1.75 in the previous year.

The company reported that trade receivables increased significantly to ₹3990.00 lakh as of March 31, 2026, from ₹1889.70 lakh in the previous year. Cash and cash equivalents improved to ₹35.23 lakh from ₹11.11 lakh. The company utilized its entire IPO proceeds of ₹1484.00 lakh for working capital requirements, general corporate purpose, and issue expenses.

Board Decisions and Compliance

The Board approved the appointment of M/s. B G KALAL & CO Chartered Accountant as internal auditor for FY27 and the re-appointment of M/s Surana and Kothari Associates LLP as Secretarial Auditor for FY27. The Board took note of the resignation of Mr. Rahul Joshi from the position of Company Secretary and Compliance Officer effective July 1, 2026. Additionally, the Board approved criteria for granting omnibus approval for related party transactions for FY27.

The company acknowledged a notice from the National Stock Exchange (NSE) regarding non-compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, and Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018. The statutory auditors, M/s R. K. Mergu & Co., issued an unmodified opinion on the audited standalone and consolidated financial results.

Consolidated Results

The consolidated financial results reflect the performance of the company and its two subsidiaries. Total consolidated revenue for FY26 was ₹16570.59 lakh, a decrease from ₹16932.38 lakh in the previous year. Profit before tax for the year stood at ₹57.64 lakh, compared to ₹446.29 lakh in FY25. The subsidiaries reported total assets of ₹12228.75 lakh as of March 31, 2026, and total revenues of ₹16569.19 lakh for the year.

Mono Pharmacare Limited disclosed that its promoters and Persons Acting in Concert have not created any encumbrance on the company's shares during the financial year ended March 31, 2026. The declaration, submitted to the National Stock Exchange of India Limited, confirms that no shares were pledged directly or indirectly by the promoter group throughout the period.

The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates periodic disclosures regarding any encumbrance created by promoters or Persons Acting in Concert over the shares of the company. The confirmation provides assurance to shareholders regarding the unencumbered status of the promoter holding.

The disclosure was signed by Panilam Lakhatariya, a Promoter, on behalf of all Promoters and Persons Acting in Concert. The document was digitally signed on July 9, 2026, and addressed to the Listing Department of the National Stock Exchange of India Limited. A copy of the declaration was also marked to the Audit Committee of Mono Pharmacare .